Log In
BCIQ
Print this Print this
 

Aurexis

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHumanized mAb against ClfA surface protein
Molecular Target ClfA
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationStaphylococcus
Indication DetailsPrevent and treat life-threatening Staphylococcus aureus infection; Treat serious hospital-associated Staphylococcus aureus bloodstream infections; Treat Staphylococcus aureus bacteremia (SAB)
Regulatory Designation
PartnerPfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today